Peter Attia· MD
Novo Nordisk told me that I think about Two thirds of the entire insulin that is sold in America is for type 2s, not for type 1s.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Novo Nordisk told me that I think about Two thirds of the entire insulin that is sold in America is for type 2s, not for type 1s.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.